問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

黃姵瑋Huang, Pei-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • freewind05@cgmh.org.tw

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃姵瑋

List

34Cases

2020-06-01 - 2029-12-31

Phase II

Active
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  • Test Drug

    Pembrolizumab (MK-3475)/ Lenvatinib (E7080/MK-7902)

Participate Sites
7Sites

Recruiting7Sites

2022-05-02 - 2023-04-18

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-12-22 - 2030-10-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-25 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-31 - 2032-12-03

Phase III

Active
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    Imlunestrant (LY3484356)ExemestaneTamoxifenAnastrozoleLetrozole

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2027-07-31

Phase II

Completed
test

  • Condition/Disease

    test

  • Test Drug

    test

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2026-08-30

Phase I

Active
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumors

  • Test Drug

    liquid

Participate Sites
7Sites

Recruiting7Sites

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2021-10-15 - 2024-06-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2020-07-24 - 2020-11-06

Phase II

Completed
An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal

  • Condition/Disease

    anal canal

  • Test Drug

    BI 754091; BI 836880

Participate Sites
4Sites

Terminated4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB